{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:40Z","timestamp":1793041960654,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82570247"],"award-info":[{"award-number":["No.82570247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00790-4","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:29:53Z","timestamp":1781252993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting"],"prefix":"10.1186","volume":"15","author":[{"given":"Shi","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"790_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","volume":"12 1","author":"H Wang","year":"2019","unstructured":"Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12 1:59.","journal-title":"J Hematol Oncol"},{"key":"790_CR2","doi-asserted-by":"publisher","first-page":"2676","DOI":"10.7150\/ijbs.108036","volume":"21 6","author":"Z Wang","year":"2025","unstructured":"Wang Z, Wang M, Wang M, Zhou R, Deng X, Ouyang X, et al. From molecular design to clinical translation: dual-targeted CAR-T strategies in cancer immunotherapy. Int J Biol Sci. 2025;21 6:2676\u201391.","journal-title":"Int J Biol Sci"},{"key":"790_CR3","doi-asserted-by":"crossref","unstructured":"Gao Y, Zhang M. CAR-T cells targeting CD79b and CD19 exhibit robust antitumour activit y against B cell lymphoma. Blood. 2025; 146 Supplement 1:5877\u20135877.","DOI":"10.1182\/blood-2025-5877"},{"issue":"Supplement 1","key":"790_CR4","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1182\/blood-2025-4111","volume":"146","author":"R Zhang","year":"2025","unstructured":"Zhang R, Li M, Zhang X, Zhao M. This is a title in sentence case:synnotch CD123 and CLL1 CAR-T can spe cifically target AML to avoid the off-target effects. Blood. 2025;146(Supplement 1):4111\u20134111.","journal-title":"Blood"},{"key":"790_CR5","doi-asserted-by":"crossref","unstructured":"Bratt A, Martin G, Phillips M, Nigrovic S, Birocchi F, Ho C et al. Triple base-edited dual targeting CD70\/33 CAR T cells to avoid cytokin e-mediated resistance in Acute Myeloid Leukemia. Blood. 2025; 146 Supplement 1:5879\u20135879.","DOI":"10.1182\/blood-2025-5879"},{"key":"790_CR6","doi-asserted-by":"crossref","unstructured":"Chen S, Rajagopalan A, Su K, Kousa A, Kaur P, Lee R et al. Non-hematotoxic Tim-3\/CD70 dual-targeting CAR T cells promote potent a nti-leukemia activity against acute myeloid leukemia. Blood. 2025; 146 Supplement 1:2345\u20132345.","DOI":"10.1182\/blood-2025-2345"},{"issue":"Supplement 1","key":"790_CR7","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1182\/blood-2025-4125","volume":"146","author":"B Wang","year":"2025","unstructured":"Wang B, Ng B, Gonzalez-Garcia P, Su K, Lee R, James S, et al. Intein-based modular assembly of multi-receptor CAR T cells. Blood. 2025;146(Supplement 1):4125\u20134125.","journal-title":"Blood"},{"issue":"Supplement 1","key":"790_CR8","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1182\/blood-2025-7624","volume":"146","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Mulens-Arias V, Espinosa-Aroca L, Vinyoles M, Martinez-Moreno A, Roca-Ho H, et al. Caramel: Dual-targeting (CD123\/CD33) CAR-T cell as a bridge to allogeneic transplantation for Relapsed\/Refractory Acute Myeloid Leukemia. preclinical Results. Blood. 2025;146(Supplement 1):7624\u20137624.","journal-title":"Blood"},{"key":"790_CR9","doi-asserted-by":"crossref","unstructured":"Moraly J, Kondo T, Achar S, Benzaoui M, Majdoul S, Mirazee J et al. Single-cell metabolic profiling of post-infusion CD22 and CD19\/CD22 CAR T-cells reveals a shift toward amino acid\u2013driven oxphos informing SLC-armored CAR design. Blood. 2025; 146 Supplement 1:502\u2013502.","DOI":"10.1182\/blood-2025-502"},{"key":"790_CR10","doi-asserted-by":"crossref","unstructured":"Zheng Y, Luo L, Ding W, Zeng K, Ma D, Luo M. Development of a novel CD19\/BCMA dual CAR-T for autoimmune diseases. Blood. 2025; 146 Supplement 1:7639\u20137639.","DOI":"10.1182\/blood-2025-7639"},{"key":"790_CR11","doi-asserted-by":"crossref","unstructured":"Guo J, Zhang A, Tian W, Zhou X, Zhao X, Cao Y et al. Enhanced efficacy and safety of optimized tandem CD19\/CD20 CAR T-cell Therapy in refractory\/relapsed B-cell lymphoma. Blood. 2025; 146 Supplement 1:2325\u20132325.","DOI":"10.1182\/blood-2025-2325"},{"issue":"Supplement 1","key":"790_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood-2025-501","volume":"146","author":"A Merchant","year":"2025","unstructured":"Merchant A, Harris B, Zhao L, Cheemalamarri S, Potluri S, Latif T, et al. CD62L enrichment achieves robust expansion and memory phenotype post-infusion in patients with LBCL treated with rondecabtagene autoleucel, an autologous, dual-targeting CD19\/CD20 CAR T-cell candidate. Blood. 2025;146(Supplement 1):501\u2013501.","journal-title":"Blood"},{"issue":"Supplement 1","key":"790_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1182\/blood-2025-570","volume":"146","author":"X-d Liu","year":"2025","unstructured":"Liu X-d, Wang H-n, Liang Y-z, Cong J, Wang L. CD19\/CD22 bispecific CAR-t cell therapy for relapsed\/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial. Blood. 2025;146(Supplement 1):570\u2013570.","journal-title":"Blood"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00790-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00790-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:30:04Z","timestamp":1781253004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00790-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["790"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00790-4","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}